Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

An open-label, single-arm, single-center, phase II clinical trial to evaluate the feasibility, efficacy and safety of Glofitamab Combination with chidamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

Trial Details

NCT ID
NCT06570447
Phase
PHASE2
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Glofitamab
  • Chidamide
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • \- To be eligible for enrollment in this study, a subject must meet all of the following criteria:
  • Signed informed consent
  • Age ≥ 18 years at the time of informed consent
  • Patients must be willing and able to comply with protocol-specified hospitalization requirements following administration of Glofitamab. Patients m…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →